Nonclinical DMPK and Toxicokinetics Consultations
Aclairo DMPK/TK consultants provide clear, reliable ADME insights and guidance in support of program advancement.
Nonclinical DMPK/Toxicokinetics Services Overview
Aclairo’s nonclinical DMPK and TK consultants help sponsors understand how a drug behaves in animals and how exposure relates to toxicological findings. This work supports candidate selection, dose justification, exposure margin calculation, and regulatory submission. Our DMPK/TK experts deliver dependable and straightforward insights to support both mechanistic and toxicological development efforts enabling our clients to make informed choices, accelerate their programs’ timelines, and control costs.
When are Nonclinical DMPK/TK Services Needed?
- Candidate selection and lead optimization
- Design, conduct and evaluation of ADME and PK data
- Route-of-administration and formulation support
- Support for IND-enabling studies and regulatory submissions
- Dose-exposure and exposure-toxicity assessment
- Nonclinical to clinical transition
- Support of GLP and non-GLP toxicology studies
- Dose selection and justification
- Regulatory submission preparation
Expertise in Nonclinical DMPK and Toxicokinetics
What sets Aclairo DMPK/TK consultants apart is the depth of our expertise. Our specialists bring decades of combined experience, ensuring that every project benefits from the best knowledge in the field. Aclairo works closely with clients to deliver strategic guidance and comprehensive PK/PD technical analysis throughout their nonclinical development programs. Our expertise extends to direct pharmacokinetic analysis and reporting for early-stage nonclinical PK and toxicology studies, focused on meeting the unique needs and objectives of each client.
Aclairo offers comprehensive DMPK/TK support across all stages of drug development, including:- Selection and screening of drug candidates
- Evaluation of protein binding, metabolism, and CYP inhibition/induction
- Assessment of transporter substrate and inhibition properties
- PK/TK analysis and reporting for both non-GLP and GLP studies
- Oversight of bioanalytical method development and validation
- Human dose and PK projections, including allometric scaling, MABEL, and exposure-based approaches
- In vitro–in vivo extrapolation (IVIVE) to predict interspecies PK or PK/PD relationships
- Preparation of expert opinion papers, and submission-ready materials, summaries, and reports
Our Nonclinical DMPK/TK Process
Aclairo DMPK/TK consultants tailor their work to the needs of each client and the nuances of their individual therapeutic. The DMPK/TK process provides the scientific bridge between early drug characterization, toxicology findings, and clinical development decisions. By integrating ADME, PK, TK, bioanalytical, and translational data, these services help define the key evidence needed to support dose selection, exposure margins, and regulatory advancement.
Program Assessment
Review of current information (pharmacology, ADME, pharmacokinetics, toxicokinetics, toxicology, formulation, and bioanalysis) to identify any potential gaps and align with clients and regulatory needs.
Strategy Development
Formulate a DMPK/TK plan to facilitate candidate progression, support IND-enabling studies, determine dosing, justify species selection, assess exposure margins, and guide long-term development.
Study Design
Develop tailored in vitro ADME, in vivo PK, toxicokinetic, metabolite, tissue distribution, formulation-bridging, and GLP toxicology studies to meet program goals.
Bioanalytical/Biomarker Planning and Oversight
Assist with selecting bioanalytical methods, planning validation strategies, scheduling sample collection, considering appropriate matrices, determining assay sensitivity, and interpreting concentration results.
Data Analysis and Interpretation
Assess PK and TK data to define exposure levels, dose proportionality, accumulation patterns, sex and species differences, and correlations between systemic exposure and toxicology outcomes.
Translational Assessment
Connect nonclinical PK/TK findings with anticipated human exposures, provide rationale for clinical starting doses, evaluate safety margins, ensure metabolite coverage, and bridge nonclinical results to clinical development.
Reporting and Submission Support
Draft or review DMPK/TK reports, interpret toxicology findings, create IND-enabling summaries, prepare regulatory briefing documents, and develop CTD sections for nonclinical and clinical submissions.
Related Services
Frequently Asked Questions
- What is the difference between DMPK and toxicokinetics?
DMPK describes how a drug is absorbed, distributed, metabolized, and eliminated to support development strategy. Toxicokinetics measures exposure during toxicology studies to relate drug levels to safety findings. - When are GLP TK studies required?
GLP TK studies are required when toxicology studies are conducted under GLP to support regulatory submissions, such as IND-enabling repeat-dose safety studies. They measure systemic exposure at toxicology dose levels, so safety findings can be interpreted relative to the intended clinical exposure. - What is IVIVE?
IVIVE, or in vitro–in vivo extrapolation, uses laboratory data such as microsomal stability, hepatocyte clearance, protein binding, or transporter activity to predict drug behavior in animals or humans. It helps support clearance prediction, dose projection, DDI risk assessment, and nonclinical-to-clinical translation. - How is human dose projection performed?
Human dose projection is performed by integrating nonclinical pharmacology, PK, TK, toxicology, exposure–response, and safety-margin data to estimate a clinically appropriate starting dose and dose range. Approaches may include allometric scaling, IVIVE, MABEL, NOAEL-based calculations, and modeling/simulation depending on the therapeutic modality and available data. - What software is used for PK analysis?
PK analysis commonly uses Phoenix WinNonlin®, NONMEM, R, SAS, and related modeling platforms. The analysis platform depends on whether the work involves NCA, compartmental modeling, POPPK, PK/PD, or reporting.
Contact us today to ensure your nonclinical ADME studies are designed and interpreted with clarity and regulatory readiness.